Pacific Biosciences (PACB) Q3 2025 earnings summary

Executive summary

• Q3 2025 revenue was $38.4M, with record consumables of $21.3M, offsetting a 33% decline in instrument revenue; sequencing gigabase output grew ~65% year-over-year, and most Revio and Vega shipments went to new customers.

• EMEA led regional growth with an 18% year-over-year revenue increase, while Americas and Asia-Pacific faced funding challenges but saw strong consumable pull-through and high utilization rates.

• Clinical market momentum accelerated with the first regulatory approval of a clinical-grade long-read sequencer in China, new partnerships, and product launches targeting clinical and population-scale genomics.

• Major technology milestones included the launch of SPRQ-Nx chemistry, expanded HiFi assay portfolio, and selection of HiFi sequencing for large-scale international research projects.

• Cash and investments at quarter-end were $298.7M, down from $389.9M at year-end 2024.

Financial highlights

• Non-GAAP gross profit for Q3 2025 was $16.2M (42% margin), up from $13.0M (33%) in Q3 2024, driven by higher consumables mix and improved manufacturing yields.

• Non-GAAP net loss was $36.8M ($0.12/share), improved from $46.0M ($0.17/share) in Q3 2024; GAAP net loss narrowed to $38.0M from $60.7M.

• Service and other revenue grew 25% year-over-year to $5.8M.

• Operating expenses decreased significantly, with non-GAAP operating expenses at $53.9M, down from $62.4M year-over-year.

• Cash and investments declined to $298.7M from $471.1M a year ago.

Outlook and guidance

• Q4 2025 revenue expected to grow ~10% sequentially, with more Revio and Vega shipments than any prior quarter in 2025.

• Full-year 2025 revenue guidance narrowed to $155–$160M, with non-GAAP gross margin expected above 40% and year-end cash/investments above $270M.

• Cash burn for 2025 projected at ~$115M, a $70M improvement over 2024, and targeting cash flow break-even by end of 2027.

• Management expects SPRQ-Nx chemistry to lower sequencing costs by up to 40%, enhancing competitiveness.

• The company does not expect to be profitable in 2025 and will continue to focus on expense reduction initiatives.